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ABSTRACT
Introduction: Leishmaniasis is a neglected tropical disease that is defined by the World Health 
Organization as vaccine preventable. Although several new candidate vaccines are in development, 
no vaccine has successfully reached the market for human use. Several species of Leishmania cause 
human disease and have co-evolved with their respective sand fly vectors. These unique relationships 
have implications for initiation of infection and vaccine development. An approach to vaccine devel-
opment for many infectious diseases is the use of controlled human infection models (CHIMs).
Areas covered: We describe the history and recent development of experimental and deliberate 
infection using Leishmania in humans and the rationale for developing a new sand fly-initiated CHIM 
to progress leishmaniasis vaccine development. Examples from other infectious diseases are discussed 
in the context of the development of a new leishmaniasis CHIM. We also reflect upon the manufacture 
of the challenge agent, practical considerations, safety, ethics, and regulatory issues.
Expert opinion: A new cutaneous Leishmania CHIM is being developed to enable testing of vaccines in 
the development pipeline. Questions remain about the use of such CHIMs to determine effectiveness of 
vaccines against visceral leishmaniasis. However, such a CHIM will be invaluable in expediting time to 
market for vaccines.
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1.1. Understanding the problem and the clinical context 
of leishmaniasis
Leishmaniasis is a neglected tropical vector-borne disease 
caused by infection with the intracellular protozoan parasite 
Leishmania. It is endemic in at least 98 countries across the 
world [1], with over 50 species of Leishmania having been 
discovered [2], of which 20 species, belonging to two subge-
nera, having the potential to cause human disease [3]. Over 
100 million people are deemed to be at risk of contracting 
leishmaniasis, with estimates suggesting 1 billion people 
reside in endemic regions [1, 4–6]. Up to 1 million new cases 
occur each year [6], with an estimated 20,000 deaths, repre-
senting a significant burden of disease [7]. Leishmaniasis is 
largely a disease of poverty and areas of endemicity show 
over-representation by low- and middle-income (LMIC) coun-
tries. Leishmaniasis causes a spectrum of disease, predomi-
nantly affecting the skin (tegumentary leishmaniasis), but 
with potential to cause fatal systemic disease (visceral leish-
maniasis; VL). The range of skin manifestations are broad 
including localized or widespread lesions with or without 
mucosal involvement. Disease pathogenesis is determined 
predominantly by the species of infecting Leishmania parasite, 
with distinct geographical regions associated both with parti-
cular parasite and vector species and specific clinical manifes-
tations, with the prefix ‘Old World’ (reflecting the Middle East, 
Africa, and Asia) and ‘New World’ (reflecting the Americas) 
often being employed. Host genetics and environmental fac-
tors also play an important role [8]. Elimination campaigns in 
South Asia have helped decrease the numbers of new cases of 
VL although substantial barriers remain [9]. Countries border-
ing the Mediterranean are also endemic for leishmaniasis, and 
sporadic cases not linked to travel have been reported in non- 
endemic settings [10]. The natural vector is the female phle-
botomine sand fly, which becomes infected as a result of 
ingestion of parasites when taking a blood meal. Over 700 
species of sand fly have been discovered to-date [2], and close 
to 100 are vectors of Leishmania that can cause human disease 
[3]. Leishmania-associated sand flies are geographically distrib-
uted in mainly tropical climates, although species are found in 
temperate climates which has implications for disease spread 
and immunity [11].
1.2. The burden of disease and issues affecting clinical 
management
The most commonly reported form of leishmaniasis is loca-
lized cutaneous leishmaniasis (CL). Typically, this results in skin 
lesions that have the ability to self-heal, with or without 
ulceration. Causative species include L. major and L. tropica 
in the Old World, and the L. mexicana complex and the L. 
(Viannia) braziliensis complex in the New World. New World 
species may also result in mucosal leishmaniasis (L. (Viannia) 
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braziliensis), diffuse cutaneous leishmaniasis (L. amazonensis) 
and disseminated cutaneous leishmaniasis (L. (Viannia) guya-
nensis). Leishmania aethiopica infection can produce the entire 
spectrum of tegumentary disease in Ethiopia [12]. Visceral 
leishmaniasis (VL), also known as kala-azar, is caused by para-
sites of the L. donovani complex. It affects the internal organs 
and is usually fatal if left untreated. Symptoms include orga-
nomegaly and end-organ damage, bone marrow suppression, 
cachexia and anorexia, persistent fever as well as an increased 
incidence of secondary infections [13,14]. In total, 90% of VL 
cases are reported from Brazil, Ethiopia, India, Kenya, Somalia, 
South Sudan and Sudan, with 70% of cases in India reported 
from a single state, Bihar [15]. VL transmission is typified in the 
Indian subcontinent by anthroponotic transmission, though 
recent reports suggest a possible canine reservoir [16]. In 
contrast, in the Americas, VL is typically zoonotic. Following 
treatment, up to 20% of patients may develop post-kala-azar 
dermal leishmaniasis (PKDL), characterized by a progressive 
maculopapular rash, which can transform into nodular erup-
tions [17]. PKDL is thought to be predominantly immunologi-
cally mediated [18], linked to persistent parasites in the skin 
lesions and patients remain infectious for sand flies [17, 19, 
20]. HIV coinfection worsens the prognosis for both VL and 
PKDL patients [21,22].
A limited number of effective anti-leishmanial drugs are 
available (reviewed elsewhere [23–25]) but risks of drug resis-
tance remain and standard care has limited efficacy in HIV co- 
infected patients. Currently no vaccines have been licensed for 
use in the prevention of human leishmaniasis, though 
considerable progress has been made in recent years and it 
is generally accepted that a vaccine to prevent one or all forms 
of leishmaniasis would have considerable public health value.
2. Controlled human infection models
2.1. A background to studies of controlled human 
infection
Controlled human infection model (CHIM) studies use deliberate 
methods of exposure of human participants to pathogens, most 
commonly to test efficacy of candidate vaccines or to understand 
disease pathogenesis. Many terms are used interchangeably to 
describe controlled deliberate infection studies on human parti-
cipants. Discussion within the field, evidenced by a workshop 
held by the Academy of Medical Sciences in 2018 [26], has 
strengthened the use of the term ‘controlled human infection 
models’ (CHIM), as most accurately and uniformly describing 
these studies. The importance of uniformity of language sur-
rounding such studies is important to ensure clarity of message 
and avoidance of confusion, particularly as such studies are 
becoming increasingly well known outside of science-literate 
audiences. The term ‘challenge’ is used commonly in reference 
to these studies, with similar terms such as ‘human challenge 
models/studies/trials,’ ‘human infection challenge,’ ‘microbial 
challenge studies,’ ‘volunteer infection studies,’ amongst many 
other variations. Infectious agents used in CHIM studies are most 
commonly referred to as the ‘challenge agent.’
Using CHIM studies to measure efficacy of interventions at 
an early stage of development has a number of advantages 
when coupled with traditional vaccine studies and immunolo-
gical analyses. In particular, immunological correlates of pro-
tection can be derived, whilst candidate vaccines can be up- 
or down-selected at an early stage of development. This can 
also be more cost-effective in preventing potentially poorly 
performing candidates heading into large scale clinical trials. 
As such, resources can be more effectively distributed in sup-
porting a larger number of candidate vaccines, enhancing the 
possibility of a successful vaccine being developed. However, 
the predictive value of CHIMs should always be considered, 
particularly when there is significant divergence between dis-
ease progression and/or endpoints in a CHIM compared to the 
disease course in a real-world endemic setting.
CHIM studies have contributed significantly to our under-
standing of many diseases and attempts at control, with new 
vaccines being tested, novel discoveries and more accurate 
translation of results as compared to animal studies. Many such 
CHIMs and prospective human infection studies exist for a multi-
tude of diseases, described in depth elsewhere [27–35]. Many 
studies using CHIM models have generated meaningful new 
data, even where they have either failed to demonstrate efficacy 
of an intervention or where testing of specific treatments has not 
taken place. For example, in prospective studies involving den-
gue virus, CHIM studies provided valuable insight into transfor-
mation to dengue hemorrhagic fever, and a source of serial 
peripheral blood mononuclear cells (PBMC), sera and plasma 
that may prove valuable for identifying determinants of disease, 
Article highlights
● Leishmaniasis control has been challenging, contributed to by a lack 
of an effective human vaccine and limited drug therapies.
● Controlled human infection models have demonstrated efficacy of 
vaccine candidates at an early stage of development. Where vaccine 
candidates have not demonstrated success using such models, such 
studies have contributed to new concepts that underpin understand-
ing of disease pathogenesis.
● Deliberate human infection using Leishmania parasite has been car-
ried out for several centuries in a practice known as leishmanization. 
Individuals in endemic areas were inoculated with live parasites that 
prevented further infection after subsequent re-exposure.
● Over the past century, deliberate exposure to Leishmania has been 
used to study methods of transmission as well as the immunology of 
disease at the host-vector-parasite interface.
● In any CHIM study it is imperative that a well-characterized infectious 
challenge agent is employed. A parasite bank for Leishmania major, 
manufactured to GMP, has been developed. It is expected that this 
parasite bank will be large enough to satisfy numerous CHIM studies 
in the future.
● Following demonstration of safety and reproducibility of uninfected 
sand fly bites and studies on the public perception of the study 
design, a CHIM protocol has received ethical approval in the UK.
● Currently, the majority of CHIM studies take place in non-endemic 
settings, later being transferred to endemic settings. This dynamic is 
challenging for a multitude of reasons. Future CHIMs may be devel-
oped directly in endemic settings, building long-term resources and 
infrastructure. The new CHIM for cutaneous leishmaniasis is expected 
to expedite the selection of promising new vaccines for progression 
to large-scale clinical trials.
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correlates of protection and other downstream comparative 
immunological analyses [31]. In a CHIM study for Streptococcus 
pneumoniae, it was shown that carriage of pneumococcus was 
functionally significant and protected against subsequent car-
riage. This could not be determined purely by using animal 
models. Furthermore, this CHIM allowed the pathogen dose 
dependency of the antibody responses to be determined [32]. 
In a norovirus CHIM, it was found that infected immunocompe-
tent hosts do not display a measurable viremia[30]. Archived 
material from this early norovirus challenge study has contribu-
ted to novel research findings in more recent studies, with 
implications for norovirus diagnostics and assays [36]. In a 
CHIM for schistosomiasis, although the impact of repeated infec-
tion in endemic settings was not reproduced, the utility of early 
diagnostic tests could be confirmed [33]. A CHIM study for 
malaria indicated that strong cellular immune responses did 
not impact on parasite growth rates, leading to a focus on 
achieving sufficient antibody titers[37]. In some cases, CHIM 
studies have been particularly beneficial where there is a lack 
of validated animal models. This is particularly true of dengue 
virus, where non-human primates do not display clinical disease 
despite measurable viremia [31,38]. CHIM studies are even being 
considered for many diseases that had previously been thought 
to have been ‘unchallengeable’ due to ethical and pathological 
reasons, such as experimental infection with bacillus Calmette- 
Guérin (BCG) as a surrogate for Mycobacterium tuberculosis [39]. 
The use of CHIMs for rapid development and testing of emerging 
viral pathogens has been realized with a CHIM for SARS-CoV-2 
currently being investigated [35].
2.2. The history of experimental Leishmania infection 
and sand fly bite on human participants
The early part of the 20th century bought with it an abun-
dance of small experiments in quick succession that improved 
the understanding of the disease, the parasite and mode of 
transmission. The first documented experimental transmission 
to humans was in 1907, using subcutaneous inoculation [40]. 
Further work suggested the association of the Leishmania 
parasite with the sand fly [41]. The role of the sand fly in 
transmission of the parasite was then confirmed in experi-
ments on human participants, although these early investiga-
tions did not expose humans directly to sandflies [42]. The first 
documented human exposure to sand flies in an experimental 
setting involved xenodiagnosis to confirm transmission to 
non-infected sand flies from infected human participants 
[43]. Further pioneering work by Adler and Theodor in the 
early 20th century successfully confirmed the transmission of 
Leishmania from phlebotomine sand flies directly to humans 
and this has been reproduced since, as well as many experi-
mental human infections using parenteral methods [44–51]. 
This early work elucidated the life cycle of the Leishmania 
parasite in the sand fly and the finding of transmission via 
sand fly bite was made. It was also demonstrated that artificial 
feeding on infected tissue was comparable to transmission 
from human to sand fly [52,53]. Subsequent studies demon-
strated transmission using different sand fly and Leishmania 
species [54–56]. Inoculation of Leishmania infantum, causing 
canine leishmaniasis, into human participants, which 
demonstrated the ability for similar Leishmania species to 
infect and manifest similar disease phenotypes across mam-
malian species, confirmed the suggestions of an infectious 
reservoir across species with relevance to human disease [57].
A long-standing practice for many centuries in Leishmania- 
endemic countries, particularly in the Middle East, was ‘leish-
manization.’ This involves inoculation of parasites transferred 
from a person with an active cutaneous lesion, to an anato-
mical site where lesion development and scarring would be 
less stigmatizing such as the buttocks. The observation was 
made that healing of the lesion protected the recipient from 
further Leishmania infections throughout their lifetime [58]. 
Leishmanization proliferated in the mid to later part of the 
20th century, notably involving service personnel involved in 
conflicts in hyperendemic areas of the Middle East. 
Approximately 2 million people underwent leishmanization 
in this setting, which included a number of refugees, and a 
significant reduction in new cases was observed [59]. After the 
cessation of the Iran–Iraq conflict, leishmanization was largely 
abandoned. Adverse effects included exacerbated localized 
reactions in comparison to the usual disease course of the 
inoculated species Leishmania major [60], and hypersensitivity 
[59]. Reliability and viability of the inoculated parasite also 
varied widely, although currently leishmanization still occurs 
sporadically in Uzbekistan [61].
More recently, the practice of leishmanization has been 
studied further to assess reproducibility and utility to study 
new vaccines and indeed for use as a potential live vaccine 
[44, 62–65]. This has been facilitated in part by improved 
parasite culture techniques [66] and improved understanding 
of good manufacturing practices (GMP). Contemporary experi-
mental infection studies have also sought to examine the 
immunological basis of infection. One study attempted to 
demonstrate cross-protection using exposure to L. arabica- 
infected P. papatasi in one human participant, and needle 
challenge in 3 participants [67]. The participant challenged 
by sand fly bite did not develop lesions, and all other partici-
pants developed lesions by day 250 after subsequent L. major 
challenge. A further study, using an L. major preparation made 
under GMP, demonstrated lesions in 19 out of 23 healthy 
Leishmania-naïve participants, using needle challenge[63]. 
The majority (74%) developed ulcerated lesions by day 60, 
although all healed successfully, either spontaneously or with 
treatment. Collectively, these historic human infection studies 
have laid the groundwork for developing a new CHIM that 
builds on recent advances in our understanding of 
transmission.
3. Developing a CHIM for leishmaniasis
3.1. Pathway to an effective CHIM
Numerous non-human mammalian models exist for the study 
of both cutaneous and visceral forms of disease, which have 
added significant insight in to the behavior of host and patho-
gen [68, 69]. However, the predictive power of these animal 
models in terms of human response has been called into 
question [70]. Mice are most commonly used for in vivo 
experimental Leishmania studies, although different strains of 
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mice have distinct immunological responses to Leishmania 
infection and therefore translation to clinical practice may be 
difficult to predict [71, 72], emphasizing the value of direct 
studies in humans.
Observations from CHIMs of other infectious diseases has 
suggested that the threshold for developing a CHIM is multi- 
fold: poor disease control and impact on morbidity and mor-
tality, lack of successful vaccines, a number of candidate vac-
cines in the development pipeline and/or potential candidate 
antigens, absence of effective treatments and/or evidence of 
drug resistance, and perhaps most important a treatable strain 
or species of the infectious agent relevant to clinical disease. 
Given the frequent lack of resources and economic constraints 
in the endemic settings where infectious diseases occur, pilot 
studies to develop CHIMs are often conducted in high-income 
countries (HIC), with subsequent rollout to endemic settings. 
As the regulatory and ethical issues around CHIMs become 
more established, this trend may reverse, providing an addi-
tional route for long-term research capacity building in LMICs 
and facilitating the development of CHIMs adapted to local 
settings.
Given the established feasibility of experimental human 
infection with leishmaniasis using both needle challenge and 
sand fly-initiated infection, a first step in developing a new 
CHIM is to ensure that it is effective, reproducible and safe for 
participants. As such a series of enabling studies and exercises 
are required, including establishing a well characterized and 
ideally GMP compliant parasite bank for clinical use, with 
validation of the effectiveness and acceptability of sand fly 
bite and public engagement to ensure transparency, account-
ability and acceptability (see Figure 1).
3.2. Public involvement and engagement
Public engagement and involvement is now embedded within 
healthcare and research practice in the UK [73] and elsewhere. 
Given the demonstrable impact of public involvement in driv-
ing improved study design, recruitment and retention and 
scientific outcomes, public involvement has now become a 
necessity for many funders [74]. Public involvement in CHIMs 
is particularly pertinent of late, with discussion of the accept-
ability of a SARS-CoV-2 CHIM to help control the COVID-19 
pandemic [75]. There is also significant breadth of understand-
ing of CHIM studies by the public in LMICs [76], and public 
engagement is therefore an important consideration when 
conducting novel CHIM studies in endemic studies, even 
where prior consultation has taken place [77].
There are limited studies that assess public awareness of 
issues concerning leishmaniasis [78], and until recently no 
such studies at the intersection of CHIMs and leishmaniasis. 
Parkash et al. recently described a public involvement study 
related to the development of a cutaneous leishmaniasis CHIM 
using infected sand flies [79]. Ten members of the public, 
including a National Institute for Health Research (NIHR) 
patient research ambassador and a previous CHIM study par-
ticipant were recruited to discuss the basis of a Leishmania 
CHIM, in a focus group chaired by a health psychologist. The 
study design of a proposed CHIM and underpinning rationale 
from a scientific, cost-effectiveness and ethical basis were 
discussed. Participants were invited to review draft study doc-
umentation prior to their involvement. Common themes were 
identified and analyzed to identify the importance to both 
investigators and participants, separated into 1) the accuracy 
and accessibility of written participant-facing material, 2) study 
design and 3) motivation(s) for involvement in the proposed 
research. In terms of the written material, participants made it 
clear that plain English summaries of research are important to 
Figure 1. Potential development process for a cutaneous leishmaniasis CHIM.
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engage participants and the public more broadly. Specific to a 
Leishmania CHIM, participants suggested that given the 
potential for anaphylaxis or hypersensitivity from Leishmania- 
infected sand fly bite, it was important to explicitly discuss this 
in the written material, quantifying risk and explaining mitiga-
tions. Input from participants around the theme of study 
design suggested scarring was an acceptable clinical conse-
quence from a cutaneous leishmaniasis lesion, if it remained 
localized and limited in size and a choice of anatomical site 
was given. Participants were presented with a range of possi-
ble treatment options used more broadly for leishmaniasis. Of 
these, early excision of a lesion(s) was an unexpected choice 
favored by participants. The motivations given for this choice 
being both the altruistic aspect of donating tissue for analysis 
to gain potential new insights into pathogenesis as well as a 
psychological component that the procedure may ‘remove’ 
the infection. This activity subsequently informed the devel-
opment of a study protocol to develop a CHIM [79, 80]. 
Unfortunately, no participant who had previously undergone 
treatment for leishmaniasis was able to be recruited for this 
public engagement study.
3.3. Regulatory compliance
Regulatory issues will reflect the setting in which a CHIM is to 
be conducted. In the UK for example, all studies involving an 
Investigational Medical Product (IMP), are regulated by the 
Medicines and Healthcare products Regulatory Agency 
(MHRA). An infectious challenge agent pertaining to any 
CHIM study is, however, not deemed to be an IMP and is 
therefore not bound by regulations set out by the MHRA. A 
proposed UK study to develop a new CHIM using L. major, 
does not therefore require regulatory approval from the MHRA 
[80]. However, if an IMP is to be used within the context of a 
CHIM study, for example, a vaccine trial, then the MHRA would 
give due consideration to the nature of the challenge agent in 
addition to its existing obligation to regulate any IMP. In 
general, in the UK, it is expected that all clinical trial conduct 
is nevertheless carried out in accordance with Good Clinical 
Practice (GCP). In some regions an infectious challenge agent 
is required to be regulated, as per any vaccines or other IMP, 
such as in the US [81]. In regions where there is lack of formal 
guidance specifically for conduct of CHIMs, the relevant reg-
ulatory agency concerning IMPs should be consulted for 
advice.
CHIM specific guidance varies widely by region, and no 
formal regulatory guidance yet exists in the UK. However, in 
2016 the World Health Organization released a position state-
ment on regulatory considerations for CHIM studies [81]. This 
sets out some broad considerations for conduct of CHIM 
studies related specifically to the infectious challenge agent, 
appropriateness of the use of CHIM studies, design considera-
tions, potential infrastructure and operational features and 
ethical considerations. The establishment of CHIMs in endemic 
country settings may face additional barriers, including regu-
latory capacity, risk assessment and clinical governance, as 
exemplified in the establishment of a CHIM for schistosomiasis 
in Uganda [77].
3.4. Safety & ethical considerations
Subsequent to any necessary local regulatory approval, ethical 
approval must be sought through a research ethics commit-
tee, which in the UK is conducted by the Healthcare 
Regulatory Authority (HRA). Ethical review is imperative to 
CHIM studies, to ensure ethical standards are upheld and 
research participants are protected from intended and unin-
tended harms. Some negative connotations with regard to 
deliberate human exposure to infectious disease remain, as a 
result of unethical practices in the early part of the 20th 
century. In the last 50 years, improved application and 
research techniques as well as development of informed con-
sent of participants have advanced their use, although ethical 
review is still imperative to secure public confidence in such 
studies. Several safety concerns exist with any proposed 
Leishmania CHIM, as with every other CHIM study, given the 
nature of deliberate infection. These concerns should form the 
basis of ethical review. A recent non-infected sand fly biting 
study navigated some of these issues [82], in preparation for a 
proposed CHIM for Leishmania, which has now received full 
approval by a UK NHS research ethics committee [80]. The 
mitigations for these perceived risks are discussed here. 
However, CHIMs in endemic settings may have additional 
ethical issues to overcome [83,84].
Anaphylaxis has been reported from some biting and 
hematophagous insects, although no cases of anaphylaxis 
have been linked to phlebotomine sand flies. There is, how-
ever, evidence to suggest delayed-type hypersensitivity 
against some species of phlebotomine sand fly [85]. In 
Australasia, the use of the term ‘sand fly’ encompasses non- 
phlebotomine flying insects that are associated with anaphy-
laxis and severe bite reaction [86,87]. Although these adverse 
effects associated with non-phlebotomine sand flies are not 
directly relevant, evidence from public engagement work has 
suggested that such connotations can impact on recruitment 
if not accounted for [79]. In a recent non-infected sand fly 
biting study, mitigations included robust exclusion criteria, 
including history of atopic disease, history of exaggerated 
response to insect bite and history of anaphylaxis. 
Immunosuppressed individuals were also excluded based on 
experience of leishmaniasis with immune altering conditions 
such as HIV, but also observations of the use of leishmaniza-
tion and associated prolonged lesions related to immunosup-
pressed individuals [60]. Clinicians also sought to ensure 
availability of adequate resources to deal with anaphylaxis 
and other life-threatening conditions, which included a defi-
brillator, high-flow oxygen device and parenteral adrenaline, 
as well as the presence of trained clinical staff during 
proceedings.
A number of solicited reactions following a sand fly bite are 
anticipated, including itch, pain, erythema, swelling and 
potential blister formation at the bite site. In the recent 
study using uninfected sand fly bites, no serious adverse 
events (SAEs) were reported. A clinician-recorded grading sys-
tem was also utilized for recording of objective adverse 
events, with a small number of recorded events at grade 2 
out of a possible 4, with the majority of events being graded 
as 1 (Grade 1 – mild, Grade 2 – moderate, Grade 3 – severe, 
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Grade 4 – extreme). Participants were encouraged to record 
symptomology using a daily diary card up to 21 days post- 
sand fly bite exposure. A 10-point self-reported visual analo-
gue scale was used to record local effects at the bite site such 
as itch, pain/discomfort, erythema, swelling and blistering. 
Local effects were mild with mean score of between 0 and 1 
up to day 21; localized erythema, swelling and itch were 
reported most frequently. Systemic events such as headache, 
malaise, myalgia and fever were also recorded and where 
reported were mild and attributable to 2 participants who 
had an intercurrent viral infection.
In experimental models, Leishmania persistence after clin-
ical cure is well known and contributes to both long-term 
concomitant immunity to reinfection and reactivation of clin-
ical disease. This is also observed with both HIV co-infection 
[21] and elective immunosuppression [88] in humans, and 
suggests the persistence of parasite of at least some 
Leishmania species. Hence, the likelihood of parasite persisting 
after termination of a CHIM study and the long-term conse-
quences for volunteers must be considered. Comprehensive 
literature reviews identify multiple reports associated with L. 
donovani, L. infantum and L. tropica and with various New 
World species causing tegumentary disease [89,90]. In cases 
of reactivation due to elective immunosuppression, effective 
treatment was available after temporary cessation of immuno-
suppressive drugs. In contrast, reactivation following success-
ful treatment has not been described for L. major infection. 
Clinical experience thus supports use of L. major as a challenge 
agent, whilst highlighting a difficulty for developing CHIMs 
with other species. Counterbalancing risk, there is potential 
for CHIM participants to gain benefit from participation if 
traveling to a leishmaniasis endemic region through acquisi-
tion of immunity. Given development of lesions, treatment to 
terminate infection may itself carry risks. The risks of current 
Leishmania drug treatments are well established, although a 
proposal to carry out biopsy to terminate an infection has 
been approved as part of a proposed Leishmania CHIM [80]. 
Such a biopsy is likely to carry minimal risks and would be akin 
to performing a small diagnostic biopsy which is routine 
dermatological practice for many skin conditions.
Interspecies variation of Leishmania has also allowed for 
adaptation to different climates, with the implication being 
that some species have potential for spread to non-endemic 
settings [91]. The risk of introduction of L. major to non- 
endemic settings via a CHIM study is likely to be low, given 
the absence of natural vector. The risk may be increased in 
settings where other species of Leishmania and/or sand flies 
are present and anthroponotic transmission predominates, 
although not all species of Leishmania are transmissible by 
all species of sand fly. Similarly, the ethical and regulatory 
issues related to introducing non-native Leishmania species 
into an endemic country as part of a CHIM study would 
need to be balanced against the added value of conducting 
CHIMs in an endemic country setting and the risks of using 
parasite species where propensity for reactivation is less well 
understood.
3.5. Vector-specific factors
The study of the sand fly bite reaction itself in humans has 
taken place for close to a hundred years, with evolving under-
standing of its importance in establishing disease [85,92]. The 
importance of sand fly salivary gland protein alone has also 
been reinforced with the demonstration of protection against 
further challenge with Leishmania in mouse models [93,94].
Leishmaniasis is naturally transmitted by sand flies and 
sand fly salivary components as well as sand fly microbiota 
may contribute to parasite establishment and disease progres-
sion [93–95]. Importantly, vaccines effective against needle 
challenge may not always protect against natural challenge 
[96], indicating that vaccine development programs may be 
best served not solely by using humans as the model system 
but also by incorporating a natural route of challenge.
The sand fly has a complex relationship with both host and 
parasite which is difficult to replicate in settings where the 
sand fly is absent [2,97]. Given this multifaceted relationship 
between parasite, host and vector, the use of the sand fly 
vector is an important consideration in any proposed 
Leishmania CHIM. A key issue is however the extra layer of 
complexity that using vectors poses to deliver challenge 
agents. In addition to logistical issues related to sand fly 
colony maintenance, transport and/or co-location at the clin-
ical site, vector transmission introduces issues of reproducibil-
ity of inoculum size and biting frequency that may impact 
significantly on the design and analysis of a clinical study. 
Although transmission of human infective L. (Leishmania) 
and L. (Viannia) species is restricted to phlebotomine sand 
flies, evidence suggests that non-phlebotomine vectors such 
as Culicoides [98] may play a role in the transmission of species 
belonging to the phylogenetically ancient Leishmania 
(Mundinia) subgenus. This may require adaptation of pro-
posed CHIM models to ensure vaccine protection against 
non-phlebotomine initiated infection.
A study entitled FLYBITE, a precursor to a future Leishmania 
CHIM, formalized a working protocol for using sand fly biting 
on humans. This study compared biting rates of two vectors of 
L. major, P. papatasi and P. duboscqi, evaluating efficacy of the 
procedures and participant safety. The study had two arms, 
with six participants assigned to each vector, no placebo or 
control group was employed. Five sand flies were placed 
within a sand fly biting chamber that was worn for 30 minutes 
close to the antecubital fossa of the non-dominant arm. After 
completion of feeding, participants were monitored on site for 
2 hours with subsequent follow-up until day 21. There was no 
significant difference between biting rates of both species, 
and each participant sustained at least one successful sand 
fly bite (mean 3.67 ± 1.03 bites per participant). There were no 
significant adverse effects reported, although participants 
reported expected and solicited events, including erythema 
and itch at the bite site. The experiences of participants were 
overwhelmingly positive, as evidenced by a post-study focus 
group. The study protocol and associated documents have 
been made available [99].
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3.6. Parasite selection and manufacture
CHIM studies require the use of a well-characterized challenge 
agent to ensure a reproducible attack rate and mitigate 
against adverse effects. Although challenge agents are not 
regulated by the MHRA in the UK, informal regulatory advice 
emphasizes the need for challenge agents to have established 
provenance and for characterization of challenge agent 
donors for other transmissible disease (e.g. retroviruses). In 
addition, in vitro culture supplements should be from sources 
free of agents responsible for transmissible spongiform ence-
phalopathies. Ashwin et al. have described in detail elsewhere 
a new L. major strain for use in controlled human infection 
research [100]. There are several existing parasite repositories 
that are used for experimental animal work. However, the 
provenance of the parasites they contain was insufficiently 
defined with minimal relevant clinical information from donors 
and/or relating to passage conditions. In addition, cultured 
Leishmania promastigotes may not be reliable in terms of 
their infectivity [101]. The new GMP produced clinical bank 
should suffice to serve the leishmaniasis vaccine development 
community for several years to come.
The use of L. major in vaccine research for leishmaniasis is 
of importance in two linked ways. Firstly, given that a breadth 
of clinical forms of leishmaniasis exist, it has been shown that 
L. major confers heterologous protection against species that 
cause visceral leishmaniasis [102]. Although the Leishmania 
genus shares a highly conserved genome, the relative phylo-
genetic distance between New World and Old World species 
for both cutaneous and visceral species is significant [103]. 
There is, however, some evidence for the potential for attenu-
ated Old World species to provide heterologous protection 
against New World disease [104,105]. This adds further weight 
to the notion of a pan-species vaccine. Secondly given this 
cross protection, it is expected that a controlled human infec-
tion model using L. major will be informative for evaluating 
likely protection against other species of Leishmania. 
Additionally, L. major generally causes single lesions, which 
have the potential to self-heal, and with suitable treatment 
available to successfully terminate infection, in contrast with 
many other species. Importantly no evidence exists for reacti-
vation of L. major with particular relevance to immunosup-
pression [102], and the disease course is thought to be benign 
in the overwhelming majority of individuals.
There are several novel attenuated parasite strains that may 
prove beneficial for use in a future CHIM, providing a possible 
route to using species that cause visceral disease. Attenuated 
strains, however, may show loss of virulence and therefore 
falsely reassure and conversely, depending on their mode of 
generation, may revert to wild type and therefore the poten-
tial for unexpectedly aggressive disease could emerge. A L. 
major knockout deficient in lipophosphoglycan, one of the 
primary targets at the host-parasite interface, caused no 
observable disease in mice but demonstrated persistent 
immunity to re-challenge with a virulent L. major strain [106]. 
An L. donovani centrin knockout strain, in tandem with a sand 
fly salivary gland protein conferred long-term protection in 
mice, suggesting possible use of needle challenge within a 
CHIM in the absence of a suitable vector [107]. An L. infantum 
HSP70 knockout has demonstrated heterologous protection 
following inoculation of mice, in both Old World and New 
World species [104,108]. Importantly a L. major centrin knock-
out produced using CRISPR technology has recently been 
shown to provide cross protection against fatal sand fly trans-
mitted L. donovani infection in the hamster model [109].
Leishmaniaviruses (LRVs) are symbiotic RNA viruses found 
in several species of Leishmania [110]. The role of the LRVs in 
disease is still not well understood, although they may impact 
the disease course and be linked to increased severity 
[111,112], especially in New World species causing mucocuta-
neous disease such as L. (V.) guyanensis [113,114]. The use of 
New World Leishmania species infected with LRV is therefore 
problematic for CHIM studies, requiring LRV-free strains to be 
produced, which may not accurately reproduce all aspects of 
parasite behavior. Whilst LRV1 has been found in L. major 
[115] very little is known about its relationship to disease 
caused by this species. A small study in Iran did not determine 
a clear relationship between presence of LRV and treatment 
response in L. major infection [116]. Nevertheless, absence of 
LRV1 was confirmed for the new L. major strain used for GMP 
production [100].
Given the multiple challenges posed by using vectors 
within a CHIM study, there is a potential for using needle 
challenge, as has been used in multiple previous experi-
mental Leishmania infections, if sand fly-initiated infection 
is unsuccessful. Although this has the disadvantage of lack-
ing sand fly-related factors, it may allow for fewer logistical 
challenges, and in theory can be rolled out rapidly. The 
development of a parasite bank to GMP allows for this 
possibility if, for example, the use of sand fly initiated 
human experimental infection fails or is impractical. 
However, some additional considerations related to culture 
expansion and/or the isolation of infective metacyclic pro-
mastigotes prior to inoculation may have to be considered. 
CRISPR gene deletion technology also allows for attenuated 
strains to be used in such a scenario, particularly where 
editing genomes may impact on the transmission cycle 
using sand flies [117]. This possibility may also allow for 
future live attenuated parasite vaccination strategies and 
for the use of such attenuated parasites as challenge 
agents.
Although a L. major CHIM may have predictive value for a 
heterologous vaccine, a standalone visceral or mucocutaneous 
leishmaniasis model would be gold standard for these respec-
tive diseases. Proposing use of a VL-CHIM model could lead to 
discussions of the use of xenodiagnoses to determine infec-
tiousness of participants [118]. As has been alluded to, this is 
not without significant consideration with respect to risk, in 
part due to persistence of parasites and subsequent transfor-
mation of cases to PKDL, difficulty of treatment options, and 
increased morbidity and mortality in comparison to cutaneous 
disease. Parasite persistence in visceral disease is also asso-
ciated with recrudescence after initially quiescent disease, 
which can occur potentially many years downstream. This 
can be exacerbated after both primary and acquired immuno-
deficiency, and thus the follow-up period of 6 months that has 
been suggested for a CHIM for cutaneous leishmaniasis would 
not suffice for a visceral leishmaniasis model [80].
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3.7. Study design considerations
An initial protocol for a CHIM study using the challenge strain 
described above has been developed (ClinicalTrials.gov: 
NCT04512742) [80]. This Leishmania CHIM is a clinical study 
in up to 18 healthy Leishmania-naïve participants. Initially, 
participants will be exposed to biting by P. duboscqi infected 
with L. major. An adaptive design is proposed to minimize 
unnecessary exposure of participants to Leishmania and max-
imize the likelihood of developing a reproducible CHIM. All 
participants will be continually reviewed for development of 
CL lesion and when reaching 3 mm diameter, this will be 
removed by excision biopsy. Should a subsequent lesion 
develop after excision the participants will be referred to 
clinical specialists for ongoing management. Following com-
pletion of the study procedures, a focus group will take place. 
As the aim of this study is to test efficacy of the challenge 
model, i.e. reproducibility of sand fly-initiated infection, an 
ideal situation would be if all patients in the initial cohort 
develop lesions within the 6-month post-challenge phase of 
the study. If take rate is lower, however, modifications to the 
protocol for example, a switch to an alternate vector such as P. 
papatasi would be considered.
It may be valuable to evaluate new vaccine candidates 
additionally in an endemic country-based CHIM, to more accu-
rately represent the at-risk population, though the number of 
permutations of parasite species and sand fly vector needed 
to cover all geographies is daunting. CHIMs might need to be 
modified to account for variations in differing susceptibility 
and transmission efficacy of vectors and parasite in different 
ethnicities. An established CHIM used in endemic settings 
could show different transmission dynamics in non-naïve par-
ticipants. Even where participants have not been exposed to 
Leishmania, there is a reasonably high probability of exposure 
to sand fly bites in endemic regions and therefore salivary 
gland proteins and other sand fly-derived factors. These may 
attenuate disease course and impact on the outcomes of any 
vaccine study both positively and negatively [93].
4. Expert opinion
The development of an effective CHIM for cutaneous leishma-
niasis has the potential to significantly improve the timeline 
for development of vaccines already in the pipeline and sti-
mulate discovery research on vaccines by providing a clear 
route to efficacy studies in humans. Hence, research on CHIMs 
for leishmaniasis can contribute to disease control efforts, and 
impact morbidity and mortality [119]. It remains to be deter-
mined whether CHIM studies will be able to replace conven-
tional efficacy trials, as mooted for pandemic diseases [120], 
but even if this is not the case, they are likely to guide 
decisions as to which candidates enter costly large-scale vac-
cine studies. As with other diseases, a leishmaniasis CHIM will 
also provide an opportunity to gain new insights into the early 
stages of leishmaniasis disease progression. Application of 
deep phenotyping methodology, including transcriptomics, 
metabolomics and proteomics to both blood and tissue may 
identify new pathways associated with both natural and vac-
cine-induced resistance, and help to determine in a more 
directly comparative manner, the true values of current experi-
mental models of infection.
Given the complexity of the pathogenesis of leishmaniasis, 
the broad spectrum of disease and the nature of CHIM studies, 
some outstanding questions remain. Experimental human 
infection using species that cause visceral leishmaniasis has 
been used previously [50], although even with current treat-
ments and understanding of disease course, this is unlikely to 
be part of future challenge studies. Nevertheless, within 
appropriate ethical boundaries and driven by clinical need, 
many modifications of the simple CHIM protocol could be 
envisaged. For example, future CHIM studies may wish to 
address the impact of repeated exposure to uninfected sand 
flies prior to human infection.
A first clinical study to evaluate the reproducibility of a 
CHIM for sand fly transmitted cutaneous leishmaniasis has 
gained favorable ethical and institutional approval [80], with 
recruitment due to commence shortly [121]. If successful, it is 
very likely that in the coming years, CHIMs will become incor-
porated into the pipeline for candidate vaccines for leishma-
niasis. It is acknowledged that in many arthropod-borne 
diseases such as leishmaniasis, vector-specific factors are 
important for establishing infection and therefore for deter-
mining vaccination strategy. Success of a CHIM for leishma-
niasis may encourage researchers to facilitate research 
underpinning the use of other Leishmania-transmitting vec-
tors, but also the consideration of CHIMs in other biting 
arthropod-driven diseases. An important question, however, 
for any CHIM as well as future similar models, is the extrapola-
tion of vaccine efficacy derived from these models. This is a 
challenging question and will not be answered until retro-
spective analysis following widespread testing of candidate 
vaccines.
The COVID-19 global pandemic is likely to have far-reach-
ing consequences for research funding for neglected tropical 
diseases as well as disease control. Modeling has demon-
strated that delays in the visceral leishmaniasis elimination 
target in India are probable, and the number of new cases 
are likely to rise accordingly [122]. A successful CHIM is likely 
to dramatically affect the field, reducing time to market for 
vaccines, giving greater understanding of disease at the host- 
pathogen-vector interface, and improving cost-effectiveness 
of vaccine development.
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